基于两项III期试验的综合分析,对Travoprost内腔植入物的长期安全性和有效性进行评估
I Paul Singh1, John P Berdahl2, Steven R Sarkisian3
1The Eye Centers of Racine and Kenosha, Racine, WI, USA.
Drugs
|September 6, 2024
概括
在12个月内,Travoprost室内植入物有效降低了眼内压力 (IOP),并减少了对青光眼的眼滴的需求. 这种新疗法选择表明它与蒂莫洛尔无劣,并且具有良好的安全性.
科学领域:
- 眼科医生 眼科 眼科
- 青光眼的研究研究.
- 药物输送系统是药物输送系统.
背景情况:
- 进行了两项前性,多中心,随机,双面罩,受控试验,以评估travoprost室内植入物.
- 该研究的重点是患有开角玻璃眼 (OAG) 或眼睛高血压 (OHT) 的受试者.
研究的目的:
- 评估特拉沃普罗斯特室内植入物的12个月疗效和安全性 (缓缓排泄[SE]和快速排泄[FE]用于掩盖).
- 为了比较植入物与标准治疗 (蒂莫洛尔眼液) 的性能.
主要方法:
- 1150名患有OAG或OHT的受试者接受了travoprost植入物或假药/timolol.
- 在12个月内对眼内压力 (IOP) 和局部药物使用进行了监测.
- 评估了安全参数,包括治疗出现的不良事件 (TEAE).
主要成果:
- 在SE和FE两种特拉沃普罗斯特植入物中,在降低内脏压力方面,其统计学非劣于蒂莫洛尔.
- 观察到局部IOP降低药物使用的显著减少,大多数SE植入眼睛变得无药.
- 常见的TEAE包括结膜性高血,虹膜炎和增加的内膜压力.
结论:
- 在12个月的时间里,travoprost室内植入物显示出持续和强大的内压降低效果,不低于蒂莫洛尔.
- 植入物显著降低了局部IOP降压药物的需要,具有有利的安全性.
- 这种植入物代表了OAG和OHT管理的有前途的新疗法选择.
相关概念视频
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:27Open Angle Glaucoma: Treatment
408
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
408